More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$173067444
EPS
-0.13
P/E ratio
--
Price to sales
2.17
Dividend yield
--
Beta
0.213538
Previous close
$13.40
Today's open
$13.58
Day's range
$12.84 - $13.58
52 week range
$9.01 - $22.88
show more
CEO
Stephen Griffin
Employees
235
Headquarters
Bedford, MA
Exchange
Nasdaq Global Select
Shares outstanding
13395313
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
Anika Therapeutics NASDAQ: ANIK reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts, even as it lowered its commercial channel growth outlook following slower U.S. elective surgery activity.
MarketBeat • Nov 6, 2026

Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

Anika Reports Third Quarter 2026 Financial Results
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.
GlobeNewsWire • Nov 6, 2026

Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago.
Zacks Investment Research • Nov 6, 2026

Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results before the opening of the market on Friday, November 6, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.
GlobeNewsWire • Oct 22, 2026

Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Zacks Investment Research • Sep 25, 2026

Best Momentum Stocks to Buy for August 26th
BTSG, ANIK and OPHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 26th, 2026.
Zacks Investment Research • Aug 26, 2026

Anika (ANIK) Is a Great Choice for 'Trend' Investors, Here's Why
Anika (ANIK) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zacks Investment Research • Aug 24, 2026

Anika Stock Gains 43.4% in the Past 3 Months: Here Is Why?
ANIK's strong sales momentum and raised 2026 guidance bolster investor confidence, while Cingal and Hyalofast advance its pipeline.
Zacks Investment Research • Aug 21, 2026

5 Stocks With Recent Price Strength to Enhance Your Portfolio Returns
Five stocks, including EDRY, OPHC, FET, ANIK and NESR, show strong recent price gains and earnings growth as markets rally.
Zacks Investment Research • Aug 19, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Anika Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.